200000232-9 IPOS

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/20, 31/095

A1

(11) International Publication Number: WO 99/04782

(43) International Publication Date: 4 February 1999 (04.02.99)

(21) International Application Number: PCT/GB98/02155

(22) International Filing Date: 22 July 1998 (22.07.98)

(30) Priority Data:
(1) 9715444.7 22 July 1997 (22.07.97) GB

(71) Applicants *(for all designated States except US)*: SCOTIA PHARMACEUTICALS LIMITED [GB/GB]; Scotia House, Castle Business Park, Stirling FK9 4TZ (GB). ASTA MEDICA AKTIENGESELLSCHAFT [DE/DE]; An der Pikardie 10, D–01277 Dresden (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: HORROBIN, David, Frederick [GB/GB]; Laxdale Limited, Kings Park House, Laurelhill Business Park, Stirling FK7 9JQ (GB).
(2) TRITSCHLER, Hans–Jurgen [DE/DE]; Heuchelheimer Strasse 18, D–61348 Bad Homburg (DE).

(74) Agent: PHILLIPS & LEIGH; 7 Staple Inn, Holborn, London WC1V 7QF (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

1 PD
1 appln (See PF37)
2 Invs.
A61K 31/20

(54) Title: THERAPEUTIC AND DIETARY COMPOSITIONS CONTAINING ESSENTIAL FATTY ACIDS AND BIOACTIVE DISULPHIDES

(57) Abstract

Compositions of GLA and/or other EFAs with TA or related compounds, and their use in therapy or nutrition or in preparation of compositions for therapy or nutrition, especially to improve cell membrane EFA concentration and/or (particularly in diabetic complications) impaired nerve function and blood flow.